Passage Bio Inc is a renowned biotechnology company that values innovation, scientific excellence, and patient-centered approaches. At its core, Passage Bio is committed to developing transformative gene therapies to address severe neurological disorders. The company's corporate philosophy revolves around collaboration, integrity, and a deep commitment to improving patient outcomes. With a strong focus on cutting-edge research and development, Passage Bio consistently aims to revolutionize treatment options for patients in need. By leveraging its expertise and advanced technologies, Passage Bio Inc strives to make a positive impact in the lives of individuals suffering from devastating and currently untreatable genetic disorders.

Passage Bio Inc is primarily present in the United States.

Passage Bio Inc has achieved significant milestones in its journey. The company successfully completed its initial public offering (IPO) in February 2020. In the same year, Passage Bio entered into a collaboration agreement with the University of Pennsylvania (UPenn) to advance innovative gene therapies for rare monogenic CNS disorders. Additionally, the company received Fast Track designation from the U.S. FDA for its lead product candidate, PBGM01, designed to treat patients with GM1 gangliosidosis. Passage Bio has also expanded its pipeline to include therapies for other rare genetic disorders. These achievements demonstrate Passage Bio Inc's commitment to advancing groundbreaking gene therapies and providing potential treatment options for patients in need.

Passage Bio Inc is a biotechnology company specializing in genetic medicines for rare, debilitating diseases. Founded in 2017, Passage Bio aims to develop transformative therapies utilizing its proprietary Passage Bio Knowledge Platform. The company focuses on creating gene therapies capable of addressing the underlying genetic cause of diseases. With a team of seasoned experts and strategic collaborations, Passage Bio strives to deliver innovative treatments for patients with severe genetic disorders. By harnessing the potential of genetic medicine, Passage Bio Inc aspires to revolutionize the field and improve the lives of individuals affected by rare diseases.

The main competitors of Passage Bio Inc in the market include companies such as bluebird bio, Avrobio, and Avexis.

Passage Bio Inc is primarily active in the biotechnology industry.

The business model of Passage Bio Inc revolves around developing transformative therapies for rare monogenic central nervous system (CNS) disorders. The company utilizes a cutting-edge platform technology called AAV-Delivered Gene Therapy, which aims to correct genetic mutations responsible for certain CNS diseases. Passage Bio Inc's strategic approach involves collaborating with leading research centers, academic institutions, and industry experts to advance potential treatments. By focusing on precision medicine, the company aims to provide innovative gene therapies that target the root cause of these rare diseases. Passage Bio Inc is committed to improving the lives of patients affected by CNS disorders through its research and development efforts.

Коефициентът на цена спрямо печалбата (КЦП) на Passage Bio е -0,70.

Коефициентът на цена към оборот (KUV) на Passage Bio е 0.

AlleAktien качественият резултат за Passage Bio е 1/10.

Приходите не могат да бъдат изчислени в момента за Passage Bio.

очаквана Passage Bio печалба е -41,46 млн. USD.

Passage Bio Inc is a biopharmaceutical company focused on developing innovative gene therapy products for rare, genetic diseases. The company collaborates closely with leading academic and industrial partners to advance its research and development programs. The business models of Passage Bio Inc are diverse and include both the development of its own products and collaborations with other companies and institutions to develop new therapies for a broader range of diseases. The company works closely with patient groups to ensure that its products are tailored to the needs and requirements of the patients. The key products of Passage Bio Inc are gene therapies that aim to treat the underlying genetic causes of various diseases. Their products are designed to correct the absence or malfunction of one or more genes in specific body cells to restore or improve the normal function of the affected tissue. Due to their expertise and experience in the development of gene therapy products, Passage Bio's business areas have focused on various therapy areas. The company's products and services currently include gene therapies for monogenic diseases of the nervous system such as frontotemporal dementia (FTD) and Krabbe disease. Furthermore, the company continues to expand its pipeline of gene therapy products for various other medical conditions. Passage Bio Inc adopts an innovative approach to the development of gene therapy treatments and is interested in developing new and effective methods for the production, delivery, and administration of gene therapies. The company also engages in various collaborations with other companies and institutions to develop and bring to market new therapies for a broader range of diseases. In line with its business model, Passage Bio Inc combines its own research and development projects with collaborations with other companies and institutions. The company works closely with patient groups to develop its products according to the needs and requirements of the patients. Another important aspect of Passage Bio Inc's business model is its close collaboration with leading academic and industrial partners to provide a broader range of gene therapy products and services. In summary, the business model of Passage Bio Inc aims to develop innovative gene therapy products for rare genetic diseases. The company engages in research and development of its own products but also collaborates closely with other companies and institutions to develop new therapies for a broader range of diseases. The close collaboration with patient groups and leading academic and industrial partners is an important component of Passage Bio Inc's business model.

Passage Bio разпределя дивидента от 0 USD на плащания годишно.

Дивидентата за Passage Bio в момента не може да бъде изчислена или компанията не разпределя дивиденти.

ISIN на Passage Bio е US7027121000.

WKN на Passage Bio е A2P0EQ.

Тикерът на Passage Bio е PASG.

През последните 12 месеца Passage Bio изплати дивиденда в размер на . Това съответства на дивидендна доходност от около . За следващите 12 месеца се очаква Passage Bio да изплати дивиденда в размер на 0 USD.

Дивидентната доходност на Passage Bio в момента е .

Passage Bio изплаща дивидент на тримесечие. Той се разпределя в месеците .

Passage Bio платеше дивиденда всяка година през последните 0 години.

За идните 12 месеца се очакват дивиденти в размер на 0 USD. Това съответства на дивидентна доходност от 0 %.

Passage Bio се отнася за сектор 'Здраве'.

За да получите последното дивидентно плащане от Passage Bio на 12.02.2025 г. в размер на 0 USD, трябваше да притежавате акцията в портфейла си преди Ex-деня на 12.02.2025 г..

Последното дивидентно плащане беше извършено на 12.02.2025 г..

През година 2024 Passage Bio изплати 0 USD под формата на дивиденти.

Дивидентите от Passage Bio се изплащат в USD.